Amantadine Dosing for Parkinson's Disease
For Parkinson's disease, start amantadine at 100 mg once daily and titrate to 100 mg twice daily (200 mg/day total) after one week, with dose reductions mandatory for patients ≥65 years or those with renal impairment. 1
Standard Dosing Regimen
The FDA-approved dosing for Parkinson's disease follows a structured approach 1:
- Initial dose: 100 mg once daily for patients with serious medical illnesses or those on high doses of other antiparkinson drugs
- Standard maintenance: 100 mg twice daily (200 mg/day total) after 1-2 weeks at the lower dose
- Maximum dose: Up to 400 mg/day in divided doses for patients with suboptimal response at 200 mg/day, though this requires close physician supervision
- Onset of action: Typically within 48 hours
Critical Dose Adjustments for Renal Impairment
Amantadine is primarily renally cleared, making dose adjustment essential based on creatinine clearance 1, 2. The elimination half-life dramatically increases from 11.8 hours in normal renal function to 8.3 days in hemodialysis patients 3.
Renal Dosing Algorithm 1:
| Creatinine Clearance | Dosing Regimen |
|---|---|
| 30-50 mL/min/1.73m² | 200 mg on day 1, then 100 mg daily |
| 15-29 mL/min/1.73m² | 200 mg on day 1, then 100 mg every other day |
| <15 mL/min/1.73m² | 200 mg every 7 days |
| Hemodialysis | 200 mg every 7 days |
Hemodialysis removes negligible amounts of amantadine, so supplemental dosing post-dialysis is not required 1, 3.
Age-Related Considerations
For patients ≥65 years, the maximum daily dose should not exceed 100 mg regardless of renal function estimates, as renal clearance declines with age and elderly patients (particularly women with smaller body size) experience higher rates of CNS side effects 4. The apparent plasma clearance in elderly patients (0.10 L/hr/kg) is significantly lower than in younger adults 1.
Toxicity Thresholds and Monitoring
Plasma amantadine concentrations >3000 ng/mL are associated with CNS toxicity including myoclonus, hallucinations, and delirium 5, 6. Recent evidence suggests an exploratory threshold of 1776 ng/mL may predict CNS toxicity with excellent discrimination 7. Risk factors for toxicity include:
- Age ≥77 years
- Creatinine clearance <40 mL/min
- Higher amantadine dosage
- Elevated serum creatinine 7
Monitor patients closely when renal function deteriorates, as even standard doses can lead to toxic accumulation 6. Consider measuring plasma amantadine concentration when patients develop new tremor, gait disturbance, or psychiatric symptoms.
Clinical Efficacy Considerations
While all amantadine formulations reduce levodopa-induced dyskinesia (standardized mean difference -1.32), immediate-release amantadine also improves motor fluctuations (mean difference in OFF time: -0.75 hours) 8.
Loss of efficacy after several months is common—benefit may be regained by either:
- Increasing dose to 300 mg daily, or
- Temporary discontinuation for several weeks followed by reinitiation 1
Common Pitfalls
- Failing to adjust for renal function: Even "normal" serum creatinine may mask significant renal impairment in elderly patients with reduced muscle mass
- Overlooking drug accumulation: The half-life extends to days in renal impairment, requiring weekly rather than daily dosing 3
- Missing early toxicity signs: New-onset tremor or psychiatric symptoms warrant immediate amantadine level assessment and dose reduction 6
- Inadequate monitoring in elderly: Women ≥65 years are particularly susceptible to side effects at 100 mg daily doses 9